Corbion NV

Corbion announced second-quarter organic sales growth of 8.5% to €337.4 million and Adjusted EBITDA of €51.0 million, while refining its full-year 2026 Adjusted EBITDA margin outlook to above 16% from approximately 17%. For the first half of 2026, organic sales growth was 2.1% with volume/mix up 4.0% and pricing down 1.9%, resulting in sales of €631.1 million and Adjusted EBITDA of €88.8 million. The company maintained its full-year organic sales growth guidance of 3% to 6% and free cash flow forecast of €85 million to €90 million. CEO Olivier Rigaud cited strong volume/mix momentum in both Functional Ingredients & Solutions and Health & Nutrition, and expects margins to improve in the second half driven by cost savings, price increases, and continued positive volume/mix development.

The global polymeric biomaterials market is projected to grow from USD 69.55 billion in 2024 to USD 267.25 billion by 2034, at a compound annual growth rate of 15.86%, according to a new report from Zion Market Research. The polylactic acid product segment held a dominant 28% revenue share in 2024, driven by its biodegradability and versatility in applications such as drug delivery and tissue engineering. By application, orthopedics led with a 29% share, fueled by rising demand for joint replacements and bone scaffolds. Asia-Pacific is expected to maintain its leading regional position, supported by healthcare expansion and investments in regenerative medicine in countries like China, Japan, and India. Key companies profiled include BASF, DuPont, Evonik Industries, and Corbion.